He said customers are primarily plastic or cosmetic surgeons treating body-contouring patients, including patients who have experienced weight loss associated with GLP-1 medications. The company also showcased Renuvion and AYON at Miami Swim Week through its “Body by Apyx” event, which featured Renuvion patients discussing their treatment experiences and walking a runway. The outlook assumes surgical aesthetics revenue of $54 million to $55 million and OEM revenue of approximately $5 million. About Apyx Medical (NASDAQ:APYX)Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.